trending Market Intelligence /marketintelligence/en/news-insights/trending/uzkbyw128qxyqtclowucfa2 content esgSubNav
In This List

Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Mundipharma launches opioid dependence drug in EU, triggers €3M payment to Orexo

Orexo AB (publ) said that its partner Mundipharma GmbH has launched opioid dependence treatment Zubsolv in the EU, triggering a milestone payment of €3 million from Mundipharma.

Germany-based Mundipharma gained the rights to Zubsolv outside the U.S. in a June 2016 agreement with the Swedish drugmaker.

The treatment is in the form of a tablet, containing buprenorphine and naloxone, that is placed under the tongue.

Recently, Mylan NV and Dr. Reddy's Laboratories Ltd. gained the U.S. Food and Drug Administration's approval to market generic versions of Indivior PLC's Suboxone film, also a combination of buprenorphine and naloxone.